Results 11 to 20 of about 162,041 (218)
Treating C3 glomerulopathy with eculizumab [PDF]
BMC Nephrology, 2018 Background C3 glomerulopathy (C3G) is a rare, but severe glomerular disease with grim prognosis. The complex pathogenesis is just unfolding, and involves acquired as well as inherited dysregulation of the alternative pathway of the complement cascade ...
Thomas Welte +7 more
doaj +5 more sources
Dense Deposit Disease and C3 Glomerulopathy
Seminars in Nephrology, 2013 SummaryC3 glomerulopathy refers to those renal lesions characterized histologically by predominant C3 accumulation within the glomerulus, and pathogenetically by aberrant regulation of the alternative pathway of complement.
Thomas D Barbour +2 more
exaly +4 more sources
Evaluation of the children with C3 glomerulopathy
Saudi Journal of Kidney Diseases and Transplantation, 2020 C3 glomerulopathy (C3G) is a clinical spectrum that presents with a variety of symptoms, ranging from a mild disease with asymptomatic microhematuria and/or proteinuria to severe disease with nephritic or nephrotic syndrome and renal impairment.
Ayse Seda Pinarbasi +5 more
doaj +5 more sources
Update on C3 glomerulopathy [PDF]
Nephrology Dialysis Transplantation, 2014 C3 glomerulopathy refers to a disease process in which abnormal control of complement activation, degradation or deposition results in predominant C3 fragment deposition within the glomerulus and glomerular damage.
Ruseva, MM, Pickering, MC, Barbour, TD
core +5 more sources
C3 glomerulopathy: consensus report. [PDF]
Kidney International, 2013 C3 glomerulopathy is a recently introduced pathological entity whose original definition was glomerular pathology characterized by C3 accumulation with absent or scanty immunoglobulin deposition.
LAVIN, PETER
core +10 more sources
Remissions and progression of C3 glomerulopathy
Терапевтический архив, 2022 Aim. To analyze the outcomes of C3-glomerulopathy (C3-GP) and determine the associated factors. Materials and methods. A retrospective single-center study included 60 patients with newly diagnosed C3-GP (with primary C3-GP pC3-GP 82%). Of these, 48 (
Anna V. Karunnaya +1 more
doaj +3 more sources
Current and Emerging Therapies for C3 Glomerulopathy and Primary (Idiopathic) Immune Complex Membranoproliferative Glomerulonephritis. [PDF]
Kidney Int RepC3 glomerulopathy (C3G) and primary (idiopathic) immune complex membranoproliferative glomerulonephritis (IC-MPGN) are rare kidney diseases characterized by dysregulation of the complement system and progressive deposition of C3 and its breakdown ...
Kavanagh D +8 more
europepmc +2 more sources
Glomerular C4d Staining Does Not Exclude a C3 Glomerulopathy
Kidney International Reports, 2019 Introduction: C4d, an early product in the classical/lectin complement pathway has shown potential in the evaluation of C3 glomerulopathy where its absence would support an alternative pathway abnormality.
Geetika Singh +11 more
doaj +2 more sources
C3 glomerulopathy in cystic fibrosis: a case report
BMC Nephrology, 2018 Background C3 glomerulonephritis is a rare glomerulopathy characterized at renal biopsy by C3 deposition, alone or with scanty immunoglobulins, as well as by an electron-dense material in mesangium, subendothelial and subepithelial space.
Domenico Santoro +9 more
doaj +2 more sources
Delphi Consensus on Surrogate End Points in C3 Glomerulopathy and Primary Immune Complex-Mediated Membranoproliferative Glomerulonephritis. [PDF]
Kidney Int RepIntroduction C3 glomerulopathy (C3G) and primary immune complex–mediated membranoproliferative glomerulonephritis (IC-MPGN) are rare kidney diseases driven by complement dysregulation. Proteinuria is a commonly used clinical end point in trials involving
Caravaca-Fontán F +5 more
europepmc +2 more sources